Myriad Genetics, Inc (NASDAQ: MYGN) has seen a decline in its stock price by -2.97 in relation to its previous close of 7.91. However, the company has experienced a -3.46% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-04-08 that SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today that in connection with the hiring of Mr. Donnelly as chief commercial officer, previously announced on April 7, 2025, the Board of Directors of Myriad Genetics authorized the grant to Mr. Donnelly of restricted stock units equal to $3.75 million, comprising (i) time-based restricted stock units (RSUs) equal to $2 million and (ii) performance-based restricted stock units (PSUs) equal to $1.75 million, in each case effective as of the first day of his employment. These equity awards are inducements material to Mr. Donnelly’s entering into employment with Myriad Genetics in accordance with Nasdaq Listing Rule 5635(c)(4).
Is It Worth Investing in Myriad Genetics, Inc (NASDAQ: MYGN) Right Now?
Moreover, the 36-month beta value for MYGN is 1.98. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 5 as “overweight,” 6 as “hold,” and 1 as “sell.”
The public float for MYGN is 88.14M and currently, short sellers hold a 6.08% of that float. On April 17, 2025, MYGN’s average trading volume was 1.11M shares.
MYGN’s Market Performance
MYGN stock saw a decrease of -3.46% in the past week, with a monthly decline of -22.71% and a quarterly a decrease of -38.70%. The volatility ratio for the week is 5.29%, and the volatility levels for the last 30 days are 6.46% for Myriad Genetics, Inc (MYGN). The simple moving average for the last 20 days is -10.73% for MYGN stock, with a simple moving average of -58.69% for the last 200 days.
Analysts’ Opinion of MYGN
Piper Sandler, on the other hand, stated in their research note that they expect to see MYGN reach a price target of $12.50, previously predicting the price at $11.50. The rating they have provided for MYGN stocks is “Overweight” according to the report published on March 12th, 2025.
Craig Hallum gave a rating of “Buy” to MYGN, setting the target price at $29 in the report published on February 12th of the current year.
MYGN Trading at -26.72% from the 50-Day Moving Average
After a stumble in the market that brought MYGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.81% of loss for the given period.
Volatility was left at 6.46%, however, over the last 30 days, the volatility rate increased by 5.29%, as shares sank -22.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -40.91% lower at present.
During the last 5 trading sessions, MYGN fell by -3.90%, which changed the moving average for the period of 200-days by -68.13% in comparison to the 20-day moving average, which settled at $8.60. In addition, Myriad Genetics, Inc saw -44.02% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MYGN starting from DIAZ PAUL J, who sale 15,000 shares at the price of $22.93 back on Oct 11 ’24. After this action, DIAZ PAUL J now owns 962,378 shares of Myriad Genetics, Inc, valued at $343,950 using the latest closing price.
DIAZ PAUL J, the Officer of Myriad Genetics, Inc, proposed sale 15,000 shares at $22.93 during a trade that took place back on Oct 11 ’24, which means that DIAZ PAUL J is holding shares at $343,950 based on the most recent closing price.
Stock Fundamentals for MYGN
Current profitability levels for the company are sitting at:
- -0.14 for the present operating margin
- 0.69 for the gross margin
The net margin for Myriad Genetics, Inc stands at -0.14. The total capital return value is set at -0.12. Equity return is now at value -17.15, with -11.20 for asset returns.
Based on Myriad Genetics, Inc (MYGN), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -0.49. The debt to equity ratio resting at 0.2. The interest coverage ratio of the stock is -38.6.
Currently, EBITDA for the company is -186.1 million with net debt to EBITDA at -0.87. When we switch over and look at the enterprise to sales, we see a ratio of 0.91. The receivables turnover for the company is 6.55for trailing twelve months and the total asset turnover is 0.76. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.82.
Conclusion
To wrap up, the performance of Myriad Genetics, Inc (MYGN) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
